Oncotarget Journal Cut from Medline

New papers from a cancer journal once named as a possibly predatory publication will no longer appear in the widely used research database.

Written byKatarina Zimmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, FACTORYTHMedline—a government biomedical research database—no longer lists new research articles from a cancer journal with a troubled reputation.

Oncotarget, published by Impact Journals, was included in a now-inactive list of “possible predatory publishers” maintained by Jeffrey Beall, a librarian at the University of Colorado Denver. Beall has criticized Oncotarget’s peer review process as “questionable.”

According to Retraction Watch, Oncotarget has issued “a handful” of recent retractions. This includes a paper published earlier this year on the genetics that underlie the development of cancer that was reportedly pulled due to “data errors” and “negligence.” Retraction Watch reports that the editor-in-chief, Mikhail Blagosklonny, considered retracting the research papers of Beall’s colleagues after the journal had been added to Beall’s list and Beall alerted the journal to potential problems with the publications.

Medline is maintained by the U.S. National Library of Medicine, which gave no explanation ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies